Referanslar

  1. Gül F, Tekin E, Çankaya E, Sabaz MS, Çiloğlu Iİ, Oktay BD, et al. Clinical efficacy of a protocol-based hemoadsorption therapy in patients with septic shock. Turk J Intensive Care. 2026;24(1):49-62. https://doi.org/10.63729/TJIC.2025.679
  2. Efe S, Hanci P, Inal V. Survival benefit of resin cartridge extracorporeal blood purification therapy in patients with septic shock. Turk J Med Sci. 2024;54:128-35. https://doi.org/10.55730/1300-0144.5773
  3. Meco M, Agosteo E, Zulli P, Nisi F, Giustiniano E. Effects on mortality of blood purification techniques in severe septic shock patients. An updated Bayesian network meta-analysis of randomized controlled trials. J Crit Care. 2026;92:155330. https://doi.org/10.1016/j.jcrc.2025.155330
  4. Saavedra-Torres JS, Pinzón-Fernández MV, Nati-Castillo HA, et al. Immunodynamic disruption in sepsis: mechanisms and strategies for personalized immunomodulation. Biomedicines. 2025;13:2139. https://doi.org/10.3390/biomedicines13092139
  5. Thomas-Rüddel DO, Poidinger B, Kott M, et al. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. Crit Care. 2018;22:128. https://doi.org/10.1186/s13054-018-2050-9
  6. Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020;12:S5-S15. https://doi.org/10.21037/jtd.2019.11.63
  7. Monneret G, Lafon T, Gossez M, et al. Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases. Intensive Care Med. 2025;51:1820-32. https://doi.org/10.1007/s00134-025-08110-w
  8. Moura ELBD, Ferreira DP, Pereira RW. Presepsin as a diagnostic and prognostic biomarker of sepsis-associated acute kidney injury: a scoping review of clinical evidence. J Clin Med. 2025;14:6970. https://doi.org/10.3390/jcm14196970
  9. Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One. 2017;12:e0187015. https://doi.org/10.1371/journal.pone.0187015

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Attribution License (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır?

1.
İflazoğlu H, İnal V. The procalcitonin kinetics paradox in hemoadsorption therapy for septic shock: Infection source, immunomodulation, and biomarker reliability. Turk J Intensive Care. 2026;24(2):159-161. https://doi.org/10.63729/TJIC.2026.694